$GALT
GALECTIN THERAPEUTICS INC Stock $galt

$galt Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000119312520073907 Filed on March 16, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.440M	$1.390M	$5.970M
YoY Change	-16.28%	-22.35%	-16.27%
% of Gross Profit
Research & Development	$2.144M	$3.800M	$7.467M
YoY Change	231.89%	219.33%	15.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$3.584M	$5.190M	$13.44M
YoY Change	51.42%	73.58%	-1.21%
Operating Profit	-$3.584M		-$13.44M
YoY Change	51.42%		-1.21%
Interest Expense	$22.00K	$50.00K	$87.00K
YoY Change	0.0%	-171.43%	-74.11%
% of Operating Profit
Other Income/Expense, Net	$28.00K		$144.0K
YoY Change	-450.0%		-148.32%
Pretax Income	-$3.560M	-$5.140M	-$13.29M
YoY Change	49.58%	68.52%	-4.39%
Income Tax
% Of Pretax Income
Net Earnings	-$3.556M	-$5.140M	-$13.29M
YoY Change	49.73%	68.52%	-4.36%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$62.50K	-$121.0K	-$254.4K
COMMON SHARES
Basic Shares Outstanding	57.03M	56.89M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.33M	$47.48M	$47.48M
YoY Change	521.66%	475.52%	475.52%
Cash & Equivalents	$43.33M	$47.48M	$47.48M
Short-Term Investments
Other Short-Term Assets	$560.0K	$730.0K	$730.0K
YoY Change	9.8%	25.86%	25.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$43.88M	$48.21M	$48.21M
YoY Change	486.45%	445.84%	445.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.00K	$0.00	$80.00K
YoY Change	-27.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$227.0K	$258.0K	$170.0K
YoY Change	-34.58%	48.28%	0.0%
Total Long-Term Assets	$227.0K	$258.0K	$260.0K
YoY Change	-34.58%	48.28%	44.44%
TOTAL ASSETS
Total Short-Term Assets	$43.88M	$48.21M	$48.21M
Total Long-Term Assets	$227.0K	$258.0K	$260.0K
Total Assets	$44.11M	$48.47M	$48.47M
YoY Change	463.36%	438.16%	437.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$660.0K	$1.661M	$1.660M
YoY Change	47.32%	459.26%	453.33%
Accrued Expenses	$656.0K	$1.093M	$1.090M
YoY Change	42.92%	-27.71%	-27.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.316M	$2.820M	$2.820M
YoY Change	45.09%	33.78%	33.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$42.00K	$52.00K	$50.00K
YoY Change	-48.15%
Total Long-Term Liabilities	$42.00K	$52.00K	$50.00K
YoY Change	-48.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.316M	$2.820M	$2.820M
Total Long-Term Liabilities	$42.00K	$52.00K	$50.00K
Total Liabilities	$1.358M	$2.872M	$2.870M
YoY Change	37.45%	36.24%	36.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$219.9M	-$216.4M
YoY Change	7.13%	10.28%
Common Stock	$56.00K	$56.00K
YoY Change	24.44%	36.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.03M	$43.87M	$45.60M
YoY Change
Total Liabilities & Shareholders Equity	$44.11M	$48.47M	$48.47M
YoY Change	463.36%	438.16%	437.96%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$3.556M	-$5.140M	-$13.29M
YoY Change	49.73%	68.52%	-4.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$4.371M	-$3.760M	-$10.85M
YoY Change	33.1%	87.06%	6.57%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$219.0K		$50.47M
YoY Change	-89.07%		228.17%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	219.0K	910.0K	50.08M
YoY Change	-89.07%	658.33%	225.61%
NET CHANGE
Cash From Operating Activities	-4.371M	-3.760M	-10.85M
Cash From Investing Activities
Cash From Financing Activities	219.0K	910.0K	50.08M
Net Change In Cash	-4.152M	-2.850M	39.23M
YoY Change	224.12%	50.79%	654.37%
FREE CASH FLOW
Cash From Operating Activities	-$4.371M	-$3.760M	-$10.85M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	174000
CY2019Q4	us-gaap	Assets Assets	48467000
CY2018Q4	us-gaap	Assets Assets	9006000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47480000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8253000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	729000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6471000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5971000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7131000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	231000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	38000
CY2019	us-gaap	Interest Expense InterestExpense	87000
CY2018	us-gaap	Interest Expense InterestExpense	336000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-298000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	579000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	48209000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	8832000
CY2019Q4	us-gaap	Liabilities Liabilities	2872000
CY2018Q4	us-gaap	Liabilities Liabilities	2108000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1661000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	297000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48467000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9006000
CY2018Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	299000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2820000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2108000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	56000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	259673000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194130000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216394000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196215000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	43872000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7467000
CY2019	us-gaap	Operating Expenses OperatingExpenses	13438000
CY2018	us-gaap	Operating Expenses OperatingExpenses	13602000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-13438000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-13602000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-530000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	5175000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	87000
CY2018	us-gaap	Paid In Kind Interest PaidInKindInterest	336000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	356000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	997000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1091000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10848000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10179000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50469000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15379000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50075000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15379000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	39227000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5200000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3053000
CY2019	galt	Supplemental Dividends On Convertible Preferred Stock SupplementalDividendsOnConvertiblePreferredStock	102000
CY2018	galt	Supplemental Dividends On Convertible Preferred Stock SupplementalDividendsOnConvertiblePreferredStock	915000
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	12000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5603000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4445000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	47819000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5155263
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1683000
CY2018	galt	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	6003000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1093000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1512000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	81000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	45000
CY2018	galt	Accrued Research And Development Costs And Other AccruedResearchAndDevelopmentCostsAndOther	173000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	973000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1294000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1683000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4445000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0268
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0247
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.037
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.035
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1011875
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.01
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2098829
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.00
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1354330
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.31
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2713979
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.67
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	530000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.72
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	150993
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.83
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	92730
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.91
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000256
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.88
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	500000
CY2019	galt	Issuance Of Warrants Value IssuanceOfWarrantsValue	696000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	87000
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	336000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16053050
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17664953
CY2019Q4	galt	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	1093000
CY2018Q4	galt	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	1512000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	52000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	35000
CY2019	galt	Payment Of Preferred Stock Dividends PaymentOfPreferredStockDividends	394000
CY2018	galt	Payment Of Preferred Stock Dividends PaymentOfPreferredStockDividends	0
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39000
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001133416
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Trading Symbol TradingSymbol	GALT
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	galt	Undesignated Capital Stock Par Value UndesignatedCapitalStockParValue	0.01
CY2019Q4	galt	Undesignated Capital Stock Shares Outstanding UndesignatedCapitalStockSharesOutstanding	20000000
CY2018Q4	galt	Undesignated Capital Stock Par Value UndesignatedCapitalStockParValue	0.01
CY2018Q4	galt	Undesignated Capital Stock Shares Authorized UndesignatedCapitalStockSharesAuthorized	20000000
CY2018Q4	galt	Undesignated Capital Stock Shares Outstanding UndesignatedCapitalStockSharesOutstanding	20000000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56894642
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41190905
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56894642
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41190905
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3773000
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2019Q4	us-gaap	Security Deposit SecurityDeposit	6000
CY2018Q4	us-gaap	Security Deposit SecurityDeposit	6000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	galt	Undesignated Capital Stock Shares Authorized UndesignatedCapitalStockSharesAuthorized	20000000
CY2009Q1	galt	Stock Issuable Shares StockIssuableShares	3000000
CY2009Q1	galt	Stock Issuable Value StockIssuableValue	6000000
CY2009Q1	galt	Common Shares Issuable Upon Conversion Of Convertible Stock CommonSharesIssuableUponConversionOfConvertibleStock	2000000
CY2009Q1	galt	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	6000000
CY2016Q4	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	1008000
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12538204
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	705
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2592756
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.90
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M10D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	705
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39982000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36417000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	910000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1195000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5278000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4678000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46170000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42290000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46170000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42290000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.047
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.047
CY2019	galt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.008
CY2018	galt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.040
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.042
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.291
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.206
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	2120000
CY2019Q4	galt	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-13294000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-13900000
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	263000
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1147000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20179000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15047000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3000256
CY2019	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y2M19D
CY2019Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.88
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2592756
CY2019Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.90
CY2019Q4	us-gaap	Share Price SharePrice	2.86
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.83
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.98
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	407500
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	54865
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	517000
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P10M27D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	130490
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1409804
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	491000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4519000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	galt	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	3579642
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3579642
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52238000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39414000
CY2019Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	66000
CY2019Q2	us-gaap	Share Price SharePrice	4.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	galt	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	500
CY2010Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.20
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	47000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	48000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	103000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	90000
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P38M
CY2019Q1	galt	Lease Deposits LeaseDeposits	6000
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.1104
CY2010Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	10000
CY2010Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47000
CY2011Q4	galt	Common Shares Issuable Upon Conversion Of Convertible Stock CommonSharesIssuableUponConversionOfConvertibleStock	1667
CY2011	galt	Closing Stock Price Of Common Stock ClosingStockPriceOfCommonStock	18.00
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	594302
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11076199
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Entity Registrant Name EntityRegistrantName	GALECTIN THERAPEUTICS INC
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57031027
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	166000000
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	galt	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	2500000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	150000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	galt	Non Cash Expense Related To Extension Of Warrants NonCashExpenseRelatedToExtensionOfWarrants	6622000
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Security12b Title Security12bTitle	Common Stock
CY2019Q4	galt	Undesignated Capital Stock Value UndesignatedCapitalStockValue
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q1	galt	Non Cash Expense Related To Extension Of Warrants NonCashExpenseRelatedToExtensionOfWarrants	6622000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2019	galt	Accrued Research And Development Costs And Other AccruedResearchAndDevelopmentCostsAndOther
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019	us-gaap	Basis Of Accounting BasisOfAccounting	<table style="border-collapse: collapse; color: rgb(0, 0, 0); font-family: "times new roman"; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px; border-spacing: 0px;;width:100%;"><tr style="page-break-inside:avoid"><td style="padding-left: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="padding-left: 0px;;text-align:left;;vertical-align:top;"><div style="font-size: 10pt; font-family: "times new roman"; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nature of Business and Basis of Presentation </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Galectin Therapeutics Inc. and subsidiaries (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.</div></div><div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px">The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“Pro-Pharmaceuticals,</div> Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011.</div><div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At December 31, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>, the Company had $47,480,000 of unrestricted cash and cash equivalents available to fund future operations. The Company believes there is sufficient cash, including availability of the line of credit (see Note 8), <div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to fund currently planned operations at least through September 30, 2021. We will require more cash to fund our operations after September 30, 2021 and believe we will be able to obtain additional financing. The currently planned operations include costs related to a planned adaptively designed Phase 2b/3 clinical trial. </div></div><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While the costs of the trial and general overhead during the first stage of the trial are currently estimated to be </div></div><div style="color: rgb(0, 0, 0); font-family: "times new roman"; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">approximately</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> $125 </div><div style="color: rgb(0, 0, 0); font-family: "times new roman"; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">million, the costs and timing of such trial is not yet finalized. These costs will require additional funding. However, there can be no assurance that we will be successful in obtaining such new financing or, if available, that such financing will be on terms favorable to us. If we are unsuccessful in raising additional capital to fund operations before September 30, 2021, we may be required to cease operations.</div></div><div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all, or successfully market its products.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"></div><div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates.</div> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management’s estimates and judgments include assumptions used in stock option and warrant liability valuations, useful lives of property and equipment and intangible assets, accrued liabilities, deferred income taxes and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</div></div><div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"></div><div style="font-size:10pt; color:#000000; font-family:times new roman; font-style:normal; font-variant:normal; font-weight:400; letter-spacing:normal; margin-bottom:0pt; margin-left:4%; margin-top:6pt; orphans:2; text-align:left; text-decoration:none; text-indent:0px; text-transform:none; -webkit-text-stroke-width:0px; white-space:normal; word-spacing:0px"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk.</div> Financial instruments that subject the Company to credit risk consist of cash and cash equivalents and certificates of deposit. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed federally insured limits. The Company has no significant concentrations of credit risk.</div></div><div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-6622000
CY2019	galt	Currently Estimated Costs Of Trail And General Overhead CurrentlyEstimatedCostsOfTrailAndGeneralOverhead	125000000

Files In Submission

Name	View Source	Status
0001193125-20-073907-index-headers.html	Edgar Link	pending
0001193125-20-073907-index.html	Edgar Link	pending
0001193125-20-073907.txt	Edgar Link	pending
0001193125-20-073907-xbrl.zip	Edgar Link	pending
d862694d10k.htm	Edgar Link	pending
d862694dex211.htm	Edgar Link	pending
d862694dex231.htm	Edgar Link	pending
d862694dex311.htm	Edgar Link	pending
d862694dex312.htm	Edgar Link	pending
d862694dex321.htm	Edgar Link	pending
d862694dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
galt-20191231.xml	Edgar Link	completed
galt-20191231.xsd	Edgar Link	pending
galt-20191231_cal.xml	Edgar Link	unprocessable
galt-20191231_def.xml	Edgar Link	unprocessable
galt-20191231_lab.xml	Edgar Link	unprocessable
galt-20191231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GALT
GALECTIN THERAPEUTICS INC Stock $galt

2020 Q1 Form 10-K Financial Statement

#000119312520073907 Filed on March 16, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GALT GALECTIN THERAPEUTICS INC Stock $galt

2020 Q1 Form 10-K Financial Statement

#000119312520073907 Filed on March 16, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GALT
GALECTIN THERAPEUTICS INC Stock $galt